Bms-907351
Carcinoid Tumor
Fox Chase Cancer CenterPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
11 Active assets in the Carcinoid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Oxodotreotide RayzeBio, Inc. | Phase 3 | BB |
Paltusotine Crinetics Pharmaceuticals Inc. | Phase 3 | BB |
Everolimus RayzeBio, Inc. | Phase 3 | B |
Octreotide Pamoate RayzeBio, Inc. | Phase 3 | B |
Lanreotide RayzeBio, Inc. | Phase 3 | B |
View all 28 →
Same molecule, other indications
Bms-907351 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →